Astellas Pharma Inc. (ALPMY)
OTCMKTS
· Delayed Price · Currency is USD
9.93
+0.03 (0.30%)
Mar 28, 2025, 4:00 PM EST
Astellas Pharma Revenue
Astellas Pharma had revenue of 517.41B JPY in the quarter ending December 31, 2024, with 22.63% growth. This brings the company's revenue in the last twelve months to 1.87T, up 21.01% year-over-year. In the fiscal year ending March 31, 2024, Astellas Pharma had annual revenue of 1.60T with 5.60% growth.
Revenue (ttm)
1,867.63B JPY
Revenue Growth
+21.01%
P/S Ratio
n/a
Revenue / Employee
126.58M JPY
Employees
14,754
Market Cap
17.29B USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 1,603.67B | 85.05B | 5.60% |
Mar 31, 2023 | 1,518.62B | 222.46B | 17.16% |
Mar 31, 2022 | 1,296.16B | 46.64B | 3.73% |
Mar 31, 2021 | 1,249.53B | -51.32B | -3.94% |
Mar 31, 2020 | 1,300.84B | -5.51B | -0.42% |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.76B |
SS Innovations International | 16.04M |
Veradigm | 588.02M |
Elite Pharmaceuticals | 70.00M |
Glass House Brands | 200.90M |
Northwest Biotherapeutics | 1.60M |
Silence Therapeutics | 43.26M |
American Oncology Network | 1.76B |
Astellas Pharma News
- 7 days ago - Singlera Genomics Presented Non-Invasive Testicular Toxicity Detection with Astellas at 2025 SOT Meeting - GlobeNewsWire
- 16 days ago - Astellas Pharma: Raising New, As Yet Unanswered Questions In Stomach Cancer And Moving Their Pipeline Forward - Seeking Alpha
- 25 days ago - Astellas and YASKAWA Agree to Establish a Joint Venture Focused on Cell Therapy Manufacturing - PRNewsWire
- 4 weeks ago - Astellas and MBC BioLabs Announce the Sixth Annual Astellas Future Innovator Prize - PRNewsWire
- 6 weeks ago - U.S. FDA Approves Expanded Label for Astellas' IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy - PRNewsWire
- 6 weeks ago - Pfizer/Astellas Tout Encouraging Data From Keytruda Combo Regime In Urothelial Cancer Showing 49% Reduction In Death Risk Vs. Chemo - Benzinga
- 6 weeks ago - Pfizer and Astellas' PADCEV® (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (la/mUC) - Benzinga
- 7 weeks ago - Astellas Pharma Inc. (ALPMF) Q3 2024 Earnings Call Transcript - Seeking Alpha